DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get a Free sample for the Atopic Dermatitis Market Report:

https://www.delveinsight.com/report-store/atopic-dermatitis-market

Some of the key facts of the Atopic Dermatitis Market Report:

• The Atopic Dermatitis market size is projected to grow from approximately USD 13 billion in 2025 to nearly USD 28 billion by 2036, expanding at a CAGR of 7.0% during the forecast period from 2026 to 2036.

• In March 2026, Sanofi presented new results from its Phase III amlitelimab studies in atopic dermatitis during a late-breaking research session at the American Academy of Dermatology Annual Meeting 2026.

• In March 2026, Eli Lilly announced positive Phase III results (ADorable-1 trial) for lebrikizumab in pediatric atopic dermatitis (≥6 months), demonstrating significant improvements in skin clearance and itch, with plans for regulatory submissions for label expansion.

• In January 2026, recent dermatology updates highlighted continued expansion of novel therapies for atopic dermatitis, including newer topical and biologic agents, reflecting rapid innovation and broader treatment options across age groups.

• In September 2025, the US Food and Drug Administration approved ruxolitinib cream (Opzelura) for pediatric patients aged 2–11 years, expanding access to a topical JAK inhibitor for atopic dermatitis.

• In December 2025, Elanco Animal Health Incorporated (NYSE: ELAN) has expanded its presence in the growing canine dermatology market with USDA approval of Befrena™ (tirnovetmab), a new anti-IL31 monoclonal antibody injection for treating canine allergic and atopic dermatitis. Notably, Befrena is administered at 6 to 8-week intervals post-treatment, compared to the 4 to 8-week dosing schedule of the existing competitor, lokivetmab.

• In December 2025, Enveda, a clinical-stage biotechnology company advancing next-generation small-molecule medicines inspired by natural chemistry, has begun two simultaneous Phase 2a trials for ENV-294, a first-in-class oral small molecule being developed for moderate-to-severe Atopic Dermatitis (AD) and Asthma. Launching these Phase 2a studies marks a key milestone in the company’s efforts to realize the full therapeutic potential of ENV-294. With many patients still dependent on injectable biologics, an effective and safe oral option presents a significant opportunity, particularly for those living with AD.

• In December 2025, Kymera Therapeutics has announced promising initial findings for KT-621, the first oral STAT6 degrader to reach clinical development, showing reductions in disease severity and type 2 (Th2) inflammation comparable to biologics in patients with moderate to severe atopic dermatitis (AD). In the Phase 1b BroADen study involving 22 participants, once-daily KT-621 achieved a 63% average reduction in EASI scores within four weeks, along with rapid, meaningful itch relief and strong suppression of Th2 inflammatory biomarkers. The treatment was well tolerated, with no therapy-related adverse events reported, according to the company.

• In December 2025, Zai Lab (ZLAB) has begun a global Phase 1/1b clinical study, administering the first dose to a participant to evaluate ZL-1503, a bispecific antibody directed at IL-13 and IL-31R for the treatment of atopic dermatitis. The trial will examine the therapy’s safety, tolerability, pharmacokinetics, and early signs of efficacy. Developed in-house by Zai Lab’s discovery team, ZL-1503 is engineered with an extended serum half-life and dual action on both the IL-13 and IL-31 pathways, a combination that may offer faster therapeutic effects and enhanced overall efficacy.

• In September 2025, Phase III ASCEND trial (NCT05882877) results showed that rocatinlimab from Amgen and Kyowa Kirin delivered durable clinical improvements and maintained a favorable long-term safety profile in adults with moderate to severe atopic dermatitis (AD). The company noted that this investigational therapy targets OX40 to rebalance T-cell activity, with the goal of addressing chronic inflammation and lowering treatment burden through reduced dosing frequency.

• In June 2025, US biotechnology company TRex Bio has initiated dosing of healthy volunteers in a clinical trial evaluating TRB-061 for atopic dermatitis (AD). TRB-061, a TNFR2 agonist, is being developed to treat AD (commonly known as eczema) by activating and expanding effector regulatory T cells within tissue to help restore immune balance in inflammatory conditions.

• In March 2025, Amgen and Kyowa Kirin announced that their 24-week Phase III IGNITE trial evaluating two dose levels of rocatinlimab, a T-cell rebalancing therapy for moderate to severe atopic dermatitis (AD), successfully met its co-primary endpoints. All key secondary endpoints also achieved statistical significance over placebo. The double-blind, randomized, placebo-controlled study included 769 adults, some of whom had prior treatment with biologics or systemic Janus kinase (JAK) inhibitors.

• In March 2025, Hudson Therapeutics, the U.S. arm of Shaperon, announced that Shaperon is set to begin Phase 2b Part 2 of its clinical trial for NuGel an innovative inflammasome inhibitor aimed at treating mild to moderate atopic dermatitis. A recent kickoff meeting held in March in the U.S. marks a key step in NuGel’s global clinical progress.

• According to the estimates, the largest market size of atopic dermatitis was captured by the United States, i.e., ~USD 9,000 million in 2025.

• The atopic dermatitis market is evolving as treatment focus shifts from broad-spectrum biologics to more targeted therapies, with JAK inhibitors and IL-targeted agents driving adoption due to their favorable efficacy, safety, and expanded pediatric indications.

• Regional market dynamics show the US leading in revenue, while Japan and EU markets demonstrate steady growth, reflecting increasing diagnosis rates, broader pediatric access, and rising adoption of novel mechanisms.

• In 2025, among all the therapies for atopic dermatitis, the highest revenue is estimated to be generated by DUPIXENT, in the United States.

• According to DelveInsight’s estimates, the total prevalent cases of atopic dermatitis in the 7MM were approximately 73,243,000 in 2025.

• It has been observed that the prevalence of atopic dermatitis is higher in children (

• In 2025, among severity of atopic dermatitis in the US, mild atopic dermatitis was the most prevalent subtype (~14,739,000 cases), followed by moderate atopic dermatitis.

• The atopic dermatitis is found to be more prevalent in females than in males.

• Key Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others

• Key Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others

• The Atopic Dermatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atopic Dermatitis pipeline products will significantly revolutionize the Atopic Dermatitis market dynamics.

Atopic Dermatitis Overview

Atopic Dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by itchy, red, and dry skin. It is most frequently seen in children but can occur at any age. Atopic Dermatitis is part of a group of allergic conditions, often referred to as the atopic triad, which also includes asthma and allergic rhinitis (hay fever).

To Know in detail about the Atopic Dermatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atopic Dermatitis Market Forecast

Atopic Dermatitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Atopic Dermatitis Epidemiology Segmentation:

The Atopic Dermatitis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of Atopic Dermatitis

• Prevalent Cases of Atopic Dermatitis by severity

• Gender-specific Prevalence of Atopic Dermatitis

• Diagnosed Cases of Episodic and Chronic Atopic Dermatitis

Download the report to understand which factors are driving Atopic Dermatitis epidemiology trends @ Atopic Dermatitis Epidemiology Forecast

Atopic Dermatitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atopic Dermatitis market or expected to get launched during the study period. The analysis covers Atopic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Atopic Dermatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Atopic Dermatitis Therapies and Key Companies

• Upadacitinib (RINVOQ): AbbVie

• Amlitelimab (KY1005): Sanofi

• Bosakitug: Biosion

• Orismilast: UNION Therapeutics

• Bermekimab: Janssen Pharmaceutical

• FB825: Oneness Biotech

• Lebrikizumab: Eli Lily

• Nemolizumab: Galderma

• B244: AOBiome

• Ruxolitinib: Incyte

• Difelikefalin: Cara Therapeutics

• Roflumilast: Arcutis Biotherapeutics

• Rocatinlimab: Amgen/Kyowa Kirin

• Tapinarof: Dermavant Sciences

• KAPRUVIA/KORSUVA (difelikefalin): Cara Therapeutics

• Etrasimod: Pfizer/Arena pharmaceuticals

• BMX-010: BioMimetix

Discover more about therapies set to grab major Atopic Dermatitis market share @ Atopic Dermatitis Treatment Market

Atopic Dermatitis Market Drivers

• Rising prevalence of Atopic Dermatitis

• Escalating expenditure on healthcare

• Approvals of JAK inhibitors

• Potential Emerging Therapies for Atopic Dermatitis and pruritus

• Increasing awareness about the condition

Atopic Dermatitis Market Barriers

• Over-the-counter medications

• Outdated treatment recommendations

• Poor prognosis and treatment adherence

• Lack of timely diagnosis

• Management of Atopic Dermatitis in the primary care setting

Scope of the Atopic Dermatitis Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others

• Key Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others

• Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies

• Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Atopic Dermatitis Unmet Needs, KOL’s views, Analyst’s views, Atopic Dermatitis Market Access and Reimbursement

To know more about Atopic Dermatitis companies working in the treatment market, visit @ Atopic Dermatitis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Atopic Dermatitis Market Report Introduction

2. Executive Summary for Atopic Dermatitis

3. SWOT analysis of Atopic Dermatitis

4. Atopic Dermatitis Patient Share (%) Overview at a Glance

5. Atopic Dermatitis Market Overview at a Glance

6. Atopic Dermatitis Disease Background and Overview

7. Atopic Dermatitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Atopic Dermatitis

9. Atopic Dermatitis Current Treatment and Medical Practices

10. Atopic Dermatitis Unmet Needs

11. Atopic Dermatitis Emerging Therapies

12. Atopic Dermatitis Market Outlook

13. Country-Wise Atopic Dermatitis Market Analysis (2022–2036)

14. Atopic Dermatitis Market Access and Reimbursement of Therapies

15. Atopic Dermatitis Market Drivers

16. Atopic Dermatitis Market Barriers

17. Atopic Dermatitis Appendix

18. Atopic Dermatitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/